![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GLYCOGENESYS REPORTS PRECLINICAL CANCER DRUG FINDINGS
GLYCOGENESYS REPORTS PRECLINICAL CANCER DRUG FINDINGS
September 19, 2005
GlycoGenesys has announced that new findings about the company's cancer drug candidate GCS-100 were recently reported at the XI International Work Shop on Chronic Lymphocytic Leukemia in New York City.
The pivotal role of AKT1 in cell survival has made it an important target in cancer, cardiovascular, and neurodegenerative drug discovery. Active or up regulated AKT1 in cancer cells promotes cell survival and drug resistance and confers cell longevity in lymphomas, leukemia's and solid tumor cancers. When treated with GCS-100, a variety of lymphoma and myeloma cell lines, and chronic lymphocytic leukemia primary patient cells showed distinct down regulation of AKT1 in a dose-dependent manner.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct